# Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation

> **NCT03284762** · — · COMPLETED · sponsor: **Bayer** · enrollment: 1216 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)

## Key facts

- **NCT ID:** NCT03284762
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-11
- **Primary completion:** 2019-08-09
- **Final completion:** 2019-11-20
- **Target enrollment:** 1216 (ACTUAL)
- **Last updated:** 2020-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03284762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03284762, "Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03284762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*